| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 |
| 30 Oct 2026 |
Form 4: Rahmer Peter, See remarks
Sold 753 shares ($14K) |
| 30 Oct 2026 |
Form 4: Bergstrom Donald A, President, R&D
Sold 2,252 shares ($41.9K) |
| 30 Oct 2026 |
Form 4: Catinazzo Thomas, Chief Financial Officer
Sold 1,469 shares ($27.4K) |
| 08 Oct 2026 |
Form 4: Patel Sanjiv, Director
Sold 48,199 shares ($872K) |
| 08 Oct 2026 |
Form 4: Catinazzo Thomas, Chief Financial Officer
Sold 17,717 shares ($329K) |
| 07 Oct 2026 | 144 |
| 06 Oct 2026 | 144 |
| 09 Sep 2026 |
Form 4: Bergstrom Donald A, President, R&D
Sold 8,530 shares ($162K) |
| 09 Sep 2026 |
Form 4: Catinazzo Thomas, Chief Financial Officer
Sold 17,717 shares ($336K) |
| 09 Sep 2026 |
Form 4: Patel Sanjiv, Director
Sold 48,199 shares ($913K) |
| 28 Aug 2026 |
Form 4: Rahmer Peter, See remarks
Sold 4,508 shares ($90.3K) |
| 28 Aug 2026 |
Form 4: Svf Pauling (Cayman) Ltd, 10% owner and 2 others
Sold 6,000,000 shares ($116M) |
| 26 Aug 2026 | 144 |
| 25 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Patel Sanjiv, Director
Sold 48,199 shares ($980K) |
| 18 Aug 2026 |
Form 4: Catinazzo Thomas, Chief Financial Officer
Sold 17,717 shares ($350K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
Loading...